LDN in Clinical Practice - Andrew McCall, MB, ChB, DFM (2021 Conference) (LDN, low dose naltrexone)

The LDN Side Effect Survey Results from 2020 - Jill Brook, MA (2021 Conference) (LDN, low dose naltrexone)

Jill Brook, MA is a Research Advisor to the LDN Research Trust. In this presentation she shares the results of the 2020 LDN Side Effect Survey.

The EMF Toxicity Epidemic - Protection and Treatment - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

Longevity - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

Autoimmune thyroiditis Part 3 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

This is Part 3 of Dr. Holtorf’s 3-part series on autoimmune thyroiditis as a core cause of hypothalamic pituitary dysfunction, mitochondrial dysfunction, obesity and systemic illness. This last segment will bring it all together and give practical ways to use this information. 

Autoimmune thyroiditis Part 2 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

This is Part 2 of Dr. Holtorf’s 3-part series on autoimmune thyroiditis as a core cause of hypothalamic pituitary dysfunction, mitochondrial dysfunction, obesity and systemic illness

Autoimmune thyroiditis Part 1 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

Lyme Disease - Darin Ingels, ND (2021 Conference) (LDN, low dose naltrexone)

SIBO - Leonard Weinstock, MD (2021 Conference) (LDN, low dose naltrexone)

Opiate Receptor Drugs – To Cycle or Not to Cycle Dosing? - Paul Anderson, NMD (2021 Conference) (LDN, low dose naltrexone)